ArticleAdvanced healthcare materials2025
Redox-Active Polyphenol Red Molecularly Imprinted Polymers on Porous Gold Electrodes for Ultrasensitive, AI-Assisted Detection of Alzheimer's Biomarkers in Undiluted Biofluids.
Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Molecularly Imprinted Polymers for Biosensing: From Synthetic Recognition to Integrated Biointerfaces.Micromachines · 2026Review
- Redox Polymers in Electrochemical Biosensing: Molecular Design, Electron Transfer, and Hybrid Nanocomposites.Biosensors · 2026Review
- Overview in Electrochemical and Electrical Biosensors for Determining Blood Protein Biomarkers of Alzheimer's Disease.Biosensors · 2026Review
- Functional Foods and Micro- and Nanoplastics: Advances in Precision Nutritional Medicine for Oral-Gut-Brain Axis Health.Antioxidants (Basel, Switzerland) · 2026Review
- Review
- Review
- Redox-Active Polyphenol Red Molecularly Imprinted Polymers on Porous Gold Electrodes for Ultrasensitive, AI-Assisted Detection of Alzheimer's Biomarkers in Undiluted Biofluids.Advanced healthcare materials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Early diagnosis of Alzheimer's disease (AD) is hindered by the high cost, complexity, and centralization of current diagnostic platforms such as enzyme-linked immunosorbent assay (ELISA) and single-molecule array (SIMOA). Here, an integrated point-of-care (PoC) biosensing platform is reported based on redox-active polyphenol red molecularly imprinted polymers (pPhR MIPs) deposited on highly porous gold (HPG) electrodes for the ultrasensitive, reagent-free detection of phosphorylated tau 181 (p-tau 181) in undiluted plasma and serum. The unique electrochemical interface combines the signal-enhancing properties of HPG with the redox functionality of pPhR, eliminating the need for external redox probes. The resulting sensor achieves a limit of detection (LOD) of 980 fg mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.